Cyprotex - An Evotec Company

EVT Execute Cyprotex ADME PK Toxicology In Silico Physicochemical Profiling Drug discovery services Biotherapeutics Evotec Gene Therapy Integrated pre-clinical development Integrated CMC INDiGO Clinical development Global Regulatory Affairs Support Integrated drug discovery Therapeutic areas EVT Execute alliances

Our Services

Cyprotex specialises in in vitro and in silico ADME-Tox services. This includes in vitro ADME screening to support discovery projects, regulatory in vitro ADME and DDI studies during pre-clinical and clinical development, specialist mechanistic in vitro human and animal toxicity models (e.g., 3D models and MEA electrophysiology) and PBPK/QSAR modelling expertise.

Our dedicated team of specialists are on hand to take your enquiries:
  • Daniel Gliesche, Director, Business Development - Germany/ Austria/ Scandinavia: +49 160 1533264
  • David Cerny, Senior Director, Business Development - West Coast US: +1 609 356 6326
  • Erin Koester, Business Development Manager - East Coast US: +1 609 686 3194
  • Felix von Haniel, SVP, Business Development - General enquiries/Framingham opening 27th April/Basel workshop 4th May
  • Oksana Nikolayenko, Director, Business Development - UK/ Ire/ Spain/ Portugal/ Eastern EU: +44 7706 350245
  • Ralf Geiben Lynn, Senior Director, Business Development - East Coast US: +1 617 712 9748 
  • Tim Potter, VP, Business Development - Switzerland/ France/  Benelux/ Italy/ Israel and Asia-Pacific/ Basel workshop 4th May: +44 7761 512324
  • Tom Kaczka, Business Development Manager - West Coast US: +1 609 509 1708 
TOP